NICU

Virginia Milk Bank Seeks Donors for Hospitalized Babies

Retrieved on: 
Wednesday, March 20, 2024
Breast milk, Jaundice, Retinopathy, Nutrient, Lactation, Disease, Memory, Short bowel syndrome, CHKD, Risk, Necrotizing enterocolitis, Hospital, Milk, American Academy, Infant, Death, NICU, Life, Protein, Kidney disease, Intraparenchymal hemorrhage, Woman, Holiday, Antibody, Oxygen, Premature, Paratriathlon, Charli, ROP, Pediatrics (journal), Pediatrics, Dairy

Knowing that her breast milk was the best nutrition for Charli, Moultrie tried pumping to get her milk supply started.

Key Points: 
  • Knowing that her breast milk was the best nutrition for Charli, Moultrie tried pumping to get her milk supply started.
  • After two weeks of consistently pumping with scant results, Moultrie was grateful to learn that Charli could receive safe, pasteurized human milk through the hospital's donor milk bank.
  • The milk bank also has a legacy program for women who have lost a baby but want to donate their milk to help other infants.
  • “But there are times around the holidays and during the summer when we only have enough milk for hospitalized babies.”
    This means the milk bank is not always able to provide milk to babies who have been discharged from the hospital with a doctor’s prescription for pasteurized donor human milk.

Aspect Imaging Celebrates First Installation of Embrace® Neonatal MRI System in Canada at The Hospital for Sick Children in Toronto

Retrieved on: 
Thursday, March 28, 2024
Medical Devices, Health, Hospitals, Health Technology, Clinical Trials, General Health, The Hospital, NICU, Patient, MRI, Environment, Medical imaging

Aspect Imaging, the leading provider of compact MRI solutions, is proud to announce the successful installation of the Embrace® Neonatal MRI System at The Hospital for Sick Children (SickKids) in Toronto, Ontario, marking a significant milestone as the first installation of its kind in Canada.

Key Points: 
  • Aspect Imaging, the leading provider of compact MRI solutions, is proud to announce the successful installation of the Embrace® Neonatal MRI System at The Hospital for Sick Children (SickKids) in Toronto, Ontario, marking a significant milestone as the first installation of its kind in Canada.
  • The Embrace® Neonatal MRI System, renowned for its compact design and advanced patient-focused approach to MRI, is specifically tailored to meet the unique needs of premature and newborn patients within the environment of the neonatal intensive care unit (NICU).
  • "We are thrilled to be bringing the Embrace® Neonatal MRI System to Canada," said Wendy Slatery, Chief Commercial Officer of Aspect Imaging.
  • The addition of the Embrace® Neonatal MRI System joins the hospital's comprehensive suite of diagnostic tools, helping clinicians to care for some of their youngest patients.

Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance

Retrieved on: 
Tuesday, March 26, 2024
Automation, New Board, The Company, Pressure, ADHD, APAP, Growth, Health, Patient, Chairperson, Tablet, Hospital, Nitric oxide, Successor, NICU, GAAP, Morphine, EVOLVE, Marketing, FDA, Pharmaceutical industry

Adjusted gross profit as a percentage of sales was 62.3% for the fourth quarter of 2023, as compared to 65.9% for the fourth quarter of 2022.

Key Points: 
  • Adjusted gross profit as a percentage of sales was 62.3% for the fourth quarter of 2023, as compared to 65.9% for the fourth quarter of 2022.
  • Mallinckrodt expects fiscal 2024 Acthar Gel net revenue to decline in the low single digits, compared with fiscal 2023.
  • Mallinckrodt received FDA clearance of the INOmax EVOLVE DS Delivery System in the fourth quarter of 2023.
  • Please see the "Reconciliation of Non-GAAP Financial Guidance" included in this release for a reconciliation of GAAP and non-GAAP financial measures for the fourth quarter of 2023 and fiscal 2023.

Linden Capital Partners Acquires Alcresta Therapeutics, Inc.

Retrieved on: 
Tuesday, March 12, 2024
Device, Immobilization, Growth, CDRH, Patient, Strategic planning, Frazier Healthcare Partners, Sale, Acquisition, NICU, Therapy, FDA, Food

CHICAGO and WALTHAM, Mass., March 12, 2024 /PRNewswire/ -- Linden Capital Partners ("Linden"), a Chicago-based private equity firm focused exclusively on the healthcare industry, announced today the completion of its acquisition of Alcresta Therapeutics, Inc. ( "Alcresta"), a leader in commercializing novel enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases, from Athyrium Capital, Bessemer Venture Partners, Frazier Healthcare Partners, and HealthQuest Capital.

Key Points: 
  • CHICAGO and WALTHAM, Mass., March 12, 2024 /PRNewswire/ -- Linden Capital Partners ("Linden"), a Chicago-based private equity firm focused exclusively on the healthcare industry, announced today the completion of its acquisition of Alcresta Therapeutics, Inc. ( "Alcresta"), a leader in commercializing novel enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases, from Athyrium Capital, Bessemer Venture Partners, Frazier Healthcare Partners, and HealthQuest Capital.
  • HealthQuest Capital subsequently re-invested in Alcresta and will continue as a minority shareholder and board member.
  • Linden feels very fortunate to partner with Alcresta as it prepares for new levels of momentum and success in the years ahead."
  • We anticipate considerable growth in the years to come and appreciate the added strategic planning and investment expertise Linden and the new Board bring to Alcresta."

Calgary Health Foundation Receives Funds to Ensure Seamless Care in NICU Environments

Retrieved on: 
Thursday, February 22, 2024
Hospital, Intensive care unit, Foothills Medical Centre, Research, Infant, Patient, NICU

This funding helps to ensure the SANTS team is equipped with the same technology as the NICU, to provide consistent monitoring and seamless transfer between the care environments.

Key Points: 
  • This funding helps to ensure the SANTS team is equipped with the same technology as the NICU, to provide consistent monitoring and seamless transfer between the care environments.
  • “Through donations and collaborations like this, we are able to continue to offer world-class care and ensure a promising future for our smallest patients and their families.
  • “You don’t realize how valuable all those donations are until you’re sitting in the NICU looking at all the equipment.
  • In each of the last three years, thanks to generous supporters, the Foundation has donated $1 million for lifesaving equipment for babies.

GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024

Retrieved on: 
Tuesday, February 20, 2024
Montefiore, VUS, Genetics in Medicine, Total, Legacy, Abraxis BioScience, Partnership, Exome, DSM-IV codes, WGS, Commercial, GAAP, American College, ACMG, Genome, Genetic testing, Medicaid, Genetics, Google Health, Medical genetics, Publication, NICU, Bank

ET

Key Points: 
  • ET
    STAMFORD, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the fourth quarter and full year of 2023.
  • Exome and genome represented 27% of all test results, up from 16% in the fourth quarter of 2022 and up from 23% in the third quarter of 2023.
  • Adjusted gross margin from continuing operations expanded to 56%, up from 41% in the fourth quarter of 2022 and up from 48% in the third quarter of 2023.
  • Excluding one-time items, representative continuing operations cash burn was $23.9 million in the fourth quarter of 2023.

This International Women’s Day, Lincoln Financial Shares Research Highlighting the Financial Challenges Women Face, and Tips for Women to Address These Challenges and Help Secure Their Financial Futures

Retrieved on: 
Monday, March 4, 2024
Women, Personal Finance, Insurance, Finance, Health, Professional Services, Health Insurance, Consumer, International, Woman, Caregiver, Workplace, Weather, Education, Lincoln National Corporation, Hospital, Retirement, Life, Long-term care, LNC, Uncertainty, Male, Research, Face, NICU, Life insurance

Make life insurance a priority: The benefits of life insurance go far beyond paying funeral costs or outstanding debt.

Key Points: 
  • Make life insurance a priority: The benefits of life insurance go far beyond paying funeral costs or outstanding debt.
  • Hospital Indemnity insurance coverage that includes maternity-related and innovative NICU enhancement benefits designed specifically for expectant mothers.
  • A broad annuities portfolio that offers investors various levels of asset protection, growth potential and protected income for life.
  • Long-term care planning products and resources that can help women prepare for tough financial decisions they and their loved ones may need to make.

WubbaNub Announces Exclusive Baby Bullseye Pacifier-Plush With Target

Retrieved on: 
Tuesday, February 20, 2024
Major League Baseball, Parent, Target Corporation, MLB, Target, Phthalate, Bull Terrier, NICU, Retail

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- The award-winning, original pacifier-plush combo, WubbaNub, now offers something for even the tiniest Target fans. Available exclusively at Target.com, the Baby Bullseye WubbaNub features the patented pacifier-plush design parents love with the retailer's famous Bull Terrier mascot and Bullseye's signature red markings.*

Key Points: 
  • Available exclusively at Target.com , the Baby Bullseye WubbaNub features the patented pacifier-plush design parents love with the retailer's famous Bull Terrier mascot and Bullseye's signature red markings.
  • "Target has always been an exceptional retail partner of ours," explains Carla Schneider, CEO and Founder of WubbaNub.
  • "The opportunity to design a WubbaNub featuring the beloved Bullseye terrier was an exciting and natural next step for us."
  • The Baby Bullseye WubbaNub is now available exclusively at Target.com for $15.99 with plans to launch in stores soon.

Real-World Data on Human Milk-Based Fortification Reveals Limitations of Protocol Designs of Two RCTs

Retrieved on: 
Tuesday, February 6, 2024
Growth, Mortality, Bronchopulmonary dysplasia, Hospice and palliative medicine, NEC, Standard of care, BPD, NICU, Disease, Patient, Incidence, Sepsis, RCT, Clinical study design, Isabella Tree, BMBF, Risk, Exclusive, Vulnerable, FAAP, Birth weight, Standard, Necrotizing enterocolitis, Gestational age, Hospital, Dietary supplement

DUARTE, Calif., Feb. 6, 2024 /PRNewswire/ -- Optimizing nutrition for premature infants remains an important focus in neonatal care. More than 20 peer-reviewed studies of 5,000+ preterm infants demonstrated that, compared to bovine milk-based fortifiers (BMBF), Prolacta Bioscience's human milk-based fortifiers (HMBF) improve growth and development1-7 and provide clinically significant reductions in comorbidities.1,2,8-20 The health benefits from the use of HMBF have also shown significant annual cost savings for hospitals.8 More than 100,000 critically ill and preterm infants have received Prolacta's human milk-based nutritional products.21

Key Points: 
  • While the RCTs were intended to provide a head-to-head comparison between fortifier products, the feeding protocols fundamentally differed.
  • HMBF recommendations for best outcomes regarding the day fortification should begin and the speed at which feeds are advanced were not followed in either study.
  • Given these known risks, randomizing extremely premature infants to day-one fortification with BMBF would unjustly endanger this vulnerable patient population.
  • Extensive real-world data affirm EHMD adoption enables critical health improvements for premature infants and major cost reductions for hospitals.

Etiometry Unveils 2024 Priorities and Celebrates Milestones: Clinical Outcomes Data Show Significant Reductions in Length of Stay (LOS)

Retrieved on: 
Tuesday, January 30, 2024
Software, Practice Management, General Health, Health, Data Management, Hospitals, Health Technology, Technology, Carbon, Partnership, Abstract, Cardiology, ICU, Attention, EHR, IDO2, Hypercapnia, Hospice and palliative medicine, Research, Nursing care plan, Hospital, NICU, Analytics, Patient, Safety, Data science, FDA, SOC, Automation, QIA, Radiometer, Carbon dioxide, Algorithm, Purchasing, Length of stay, Quality, System, Pharmaceutical industry

A multicenter randomized clinical trial showed a reduction in time patients were on vasoactive medication by 18%.

Key Points: 
  • A multicenter randomized clinical trial showed a reduction in time patients were on vasoactive medication by 18%.
  • This was the first study to explore the use of algorithms in the safe de-escalation of care.
  • "The clinical outcomes data tell a compelling story of how Etiometry's platform is reshaping the landscape of critical care.
  • As the evidence highlighting the clinical efficacy of the Etiometry platform continues to grow, so does the attention from industry stakeholders.